Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Oxtellar XR, oxcarbazepine (Epliga) (formerly SPN-804)
print preview
bookmark
share with colleague
General Information
Company
Supernus Pharmaceuticals Inc.
Description
Oral, once-daily extended-release formulation of oxcarbazepine
Molecular Target
Sodium channel
Mechanism of Action
Na channel blocker
Latest Stage of Development
Marketed
Indication
Seizures
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy